R
Raymond S. McDermott
Researcher at Boston Children's Hospital
Publications - 88
Citations - 2575
Raymond S. McDermott is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 16, co-authored 68 publications receiving 1652 citations. Previous affiliations of Raymond S. McDermott include Tallaght Hospital & Mater Misericordiae Hospital.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Lorenzo Fornaro,Tomasz Olesinski,Christian Caglevic,Hyun Cheol Chung,Kei Muro,Eray Goekkurt,Wasat Mansoor,Raymond S. McDermott,Einat Shacham-Shmueli,X. Chen,Carlos Alberto Mayo,S. Peter Kang,Atsushi Ohtsu,Charles S. Fuchs,Guillermo Lerzo,Juan Manuel O'Connor,Guillermo Mendez,James Lynam,Niall C. Tebbutt,Mark Wong,Andrew Strickland,Chris Karapetis,David Goldstein,Paul Vasey,Jean-Luc Van Laethem,Eric Van Cutsem,Scott R. Berry,Mark Vincent,Bettina Muller,Felipe Rey,Angela Zambrano,Joaquin Guerra,Merete Krogh,Lene Baeksgaard,Mette Karen Yilmaz,Anneli Elme,Andrus Magi,Paivi Auvinen,Tuomo Alanko,Markus Moehler,Volker Kunzmann,Thomas Seufferlein,Peter C. Thuss-Patience,Thomas Hoehler,Georg Martin Haag,Salah-Eddin Al-Batran,Hugo Castro,Karla Lopez,Mynor Aguilar Vasquez,Mario Sandoval,Ka On Lam,Sinead Cuffe,Cathy Kelly,Ravit Geva,Ayala Hubert,Alex Beny,Baruch Brenner,Aprile Giuseppe,Alfredo Falcone,Evaristo Maiello,Rodolfo Passalacqua,Vincenzo Montesarchio,Hiroki Hara,Keisho Chin,Tomohiro Nishina,Yoshito Komatsu,Nozumo Machida,Shuichi Hironaka,Taroh Satoh,Takao Tamura,Naotaoshi Sugimoto,Haruhiko Cho,Yashushi Omuro,Ken Kato,Masahiro Goto,Ichinosuke Hyodo,Kazuhiro Yoshida,Hideo Baba,Taito Esaki,Junji Furuse,Wan Zamaniah Wan Mohammed,Carlos Hernandez Hernandez,Juan Casas Garcia,Adriana Dominguez Andrade,Katriona Clarke,Geir Hjortland,Nils Glenjen,Tomasz Kubiatowski,Jassem Jacek,Marek Z. Wojtukiewicz,Sergey Alexandrovich Lazarev,Yuri Lancukhay,Sergey Afanasayev,Vladimir Moiseyenko,Vladimir Kostorov,Svetlana Protsenko,Vadim Shirinkin,Dina Sakaeva,Natalia Fadeeva,Wei Peng Yong,Chau Hsien Matthew Ng,Barbara Robertson,Bernardo Rapaport,Graham Cohen,Lydia Dreosti,Paul Ruff,Conrad Jacobs,Gregory Landers,Waldemar Szpak,Sang-Young Roh,Jeeyun Lee,Yeul Hong Kim,Hyun Cheol Chung,Maria Alsina Maqueda,Federico Longo Munoz,Andres Cervantes Aguilar,Enrique Aranda Aguilar,Pilar Garcia Alfonso,Fernando Rivera,Jaime Feliu Batle,Roberto Pazo Cid,Kun-Huei Yeh,Jen-Shi Chen,Yee Chao,Chia Jui Yen,Oguz Kara,Suayib Yalcin,Daniel Hochhauser,Ian Chau,Al B. Benson,Veena Shankaran,Walid Shaib,Philip A. Philip,Vivek Sharma,Robert J. Siegel,Weijing Sun,Zev A. Wainberg,Ben George,Andrea J. Bullock,Samuel Myrick,Josephine Faruol,Richard M. Siegel,Timothy V. Larson,Carlos Becerra,Suresh Ratnam,Donald A. Richards,Stephen L. Riche +152 more
TL;DR: Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher and had a better safety profile than pac litaxel.
Journal ArticleDOI
Circular RNAs: Biogenesis, Function and Role in Human Diseases.
John Greene,John Greene,Anne-Marie Baird,Lauren Brady,Marvin Lim,Steven G. Gray,Raymond S. McDermott,Stephen P. Finn +7 more
TL;DR: It has been proposed that circRNA regulate gene expression at the transcriptional or post-transcriptional level by interacting with miRNAs and that circRNAs may have a role in regulating miRNA function in cancer initiation and progression.
Journal ArticleDOI
Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.
Michael J. Overman,Scott Kopetz,Raymond S. McDermott,Joseph Leach,Sara Lonardi,Heinz-Josef Lenz,Michael A. Morse,Jayesh Desai,Andrew G. Hill,Michael D. Axelson,Rebecca A. Moss,Chen-Sheng Lin,Monica V. Goldberg,Thierry André +13 more
TL;DR: Evidence supports use of nivolumab (N) in MSI-H mCRC and ipilimumab (I), a humanized anti-CTLA-4 mAb, have favorable safety & efficacy in other tumor...
Journal ArticleDOI
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad,Karim Fizazi,Viorel Jinga,Eleni Efstathiou,Peter C.C. Fong,Lowell L. Hart,Robert Jones,Raymond S. McDermott,Manfred P. Wirth,Kazuhiro Suzuki,David B. MacLean,Ling Wang,Hideyuki Akaza,Joel B. Nelson,Howard I. Scher,Robert Dreicer,Iain J. Webb,Ronald de Wit +17 more
TL;DR: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plusprednisone, however, no improvement was noted in the other primary endpoint, overall survival.
Journal ArticleDOI
Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
Wassim Abida,David Campbell,Amita Patnaik,Brieuc Sautois,Jeremy Shapiro,N. J. Vogelzang,Alan H. Bryce,Raymond S. McDermott,Francesco Ricci,Julie Rowe,Joshua Zhang,Andrew Simmons,Darrin Despain,M. Dowson,T. Golsorkhi,Simon Chowdhury +15 more
TL;DR: Consistent with prior reports, rucaparib demonstrates promising efficacy in pts with mCRPC and a germline or somatic BRCA or other DDR gene alteration.